To The Moon

Summary With Alibaba's domestic e-commerce segment, TTG, struggling, as competition intensifies and online retail sales' growth softens, can the company revive perfomance? The Cloud Intelligence Group certainly shows promise from a profits' perspective, with a 155% YoY EBITA growth in Q1 FY 25, which could outpace TTG's absolute EBITA by FY28. However, it remains to be seen whether this profit growth can continue. In the meantime, there continues to be risk from TTG's lacklustre performance. Despite attractive forward multiples, Alibaba is then a wait and watch stock, leading to a Hold rating. Robert Way When I last wrote about China’s e-commerce giant Alibaba (NYSE:

Summary PVH Corp.'s stock price has been overshadowed in recent months by its poor revenue performance and outlook. This can continue into Q2, 2024. But the stock isn't without its redeeming factors. Earnings have seen a robust rise recently, and the earnings outlook has been upgraded as well. With recent price weakness, a strong earnings outlook, as expected in Q2 2024, results in attractive market multiples. olaser Soon after my last article on the Tommy Hilfiger and Calvin Klein brands' owner PVH Corp. (NYSE:PVH), its stock price fell off a cliff following its final quarter (Q4 2023) and full-year 2023 (year endin

Summary Fed Chair Powell essentially confirmed upcoming rate cuts at his speech at the Jackson Hole economic symposium earlier today, on decreased inflation risks and increased labor market risks. He also shed light on why the US economy has stayed strong despite tight monetary policy, pointing to higher labor supply and easing off of inflation distortions following the pandemic. With the extent of rate cuts likely data dependent, upcoming GDP, labor market and inflation reports will be key. All in all, his speech is positive on the economy and if the present macro trends continue could be good for the markets too. Andrew Harnik With no surprises in Fed Chair Jerome Powell's much awaited speech a

Summary While big tobacco stocks have all seen significant increases in the past six months, Philip Morris stands out with a 32% rise. Market uncertainty and a rotation towards undervalued stocks have contributed to the growth of tobacco stocks. The company's healthy financials, particularly in its smoke-free business, are a big plus too. An earnings upgrade is positive for its dividends too. Even as a short-term price dip looks likely, PM is a good buy for passive returns over the years. Baloncici The past half year has been exceptional for tobacco stocks, with the biggest five by market capitalization ("MCap") seeing double-digit increases (see chart below). But Philip Morris (NYSE:PM) stands out even among them, seeing the biggest

Summary Recent marketing authorisation by the FDA for its NJOY vaping products gives hope that Altria might finally be able to transition to tobacco alternatives, where its lagging behind peers now. However, this can take its time. Even with far bigger rise in volume shipments for NJOY, the revenues could take a few years to make a meaningful revenue contribution. For now, the stock's likely to be guided by its dividends, which look good even as MO's price can see correction in the short-term. krblokhin Altria (NYSE:MO) might be the second biggest tobacco stock by market capitalisation, but it has woefully lagged behind peers ike Philip Morris (PM) and even British American Tobacco (

Summary After a decline in 2023 and sluggishness in the first half of 2024, BTI's price has picked up impressive pace recently, with 22% YTD gains. This can be attributed to progress on its new categories segment, with marketing authorisation received for its Vuse vapes and the segment's rising contribution to financials. At the same time, the market multiples still indicate further upside and the dividend yield looks good too. LordHenriVoton/E+ via Getty Images My last article on the Dunhill and Lucky Strike cigarette brands’ owner British American Tobacco (NYSE:BTI) (OTCPK:BTAFF) was titled “

Summary A slightly bigger-than-expected softening in annual CPI inflation in July makes a case for a Fed rate cut in September, following high unemployment rate numbers earlier this month. However, monthly inflation figures are less convincing, along with the strong latest GDP print pointing towards the probability of a cut later in the year. The timing of the cut, however, might be less significant now, considering that historically correlated times have followed a stock market rally. pcess609 Softer than expected latest inflation based on the consumer price index [CPI] at 2.9% year-on-year (YoY) in July, further confirms what has already become clear.

Summary Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too. JNJ isn't without its risk, due to Stelara's patent expirations and litigation against it, but for now, it's a safer stock than not. yuelan Among the big five pharmaceutical stocks by market capitalisation, Johnson & Johnson (NYSE:JNJ) has been the worst performer year-to-date [YTD]. While the rest of them have all seen at least some uptick, it’s actually down

Summary Rio Tinto's share price remains firmly underwhelming as iron ore prices have weakened and its prospects aren't encouraging either. While some support is possible from aluminium and copper, the company's upcoming H1 2024 results can show weakness. The trend can also continue for the full year 2024. While Rio Tinto's forward dividend yield is notable, the market multiples don't indicate price upside, making it one only for long-term dividend investors and not for capital appreciation right now. temizyurek Since I last wrote about the Australian iron ore miner Rio Tinto (NYSE:RIO) in March, its share price is up by

Summary Merck's price rise might have stalled in the past quarter, but at least for now, there's potential for some upswing again. Keytruda continues to drive revenue growth, and expansion in its usage along with positive news on other treatments and an acquisition related bump up too, the sales outlook is healthy. Concerns arise, however, regarding the earnings outlook due to the acquisition of Eyebiotech, which can impact non-GAAP EPS and potentially reduce guidance. So far, the acquisition costs aren't enough to materially affect the forward P/E relative to the stock's five-year average, though. JHVEPhoto/iStock Editorial via Getty Images Since I last wrote about the pharmaceuticals stock Merck & Co., Inc. (NYSE:MRK) in April,